| Date | Title | Description |
| 12.01.2025 | European Tech Landscape: A Surge of Innovation and Investment | The European tech scene is buzzing. A recent wave of funding, acquisitions, and innovative breakthroughs paints a vibrant picture of the continent's entrepreneurial spirit. This week alone, over 40 tech funding deals topped €1.3 billion. Th... |
| 10.01.2025 | Sciwind Biosciences Announces Global Licensing and Collaboration Agreement for Metabolic Disease Portfolio | HANGZHOU, China, Jan. 10, 2025 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, today announced a licensing and collaborati... |
| 10.01.2025 | Verdiva Bio launches with $411M Series A raise for next-gen oral and injectable treatments for obesity | Pharmatech company Verdiva Bio launched this week with an eye-watering $411 million Series A.
Focused on developing innovative therapies for obesity and other cardiometabolic disorders, Verdiva Bio is creating next-generation oral and injec... |
| 10.01.2025 | Verdiva Bio launches with $411M Series A, European startups triumph at CES, and European highest fundraisers in 2024 | This week we tracked more than 40 tech funding deals worth over €1.3 billion, and over 20 exits, M&A transactions, rumours, and related news stories across Europe. In addition to this week's top financials, we've also indexed the most i... |
| - | Verdiva Bio | “Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options.” |